189 related articles for article (PubMed ID: 15151520)
1. Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; White JM; Bochner F
Br J Clin Pharmacol; 2004 Jun; 57(6):742-55. PubMed ID: 15151520
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients.
Foster DJ; Somogyi AA; Dyer KR; White JM; Bochner F
Br J Clin Pharmacol; 2000 Nov; 50(5):427-40. PubMed ID: 11069437
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics of methadone in healthy subjects and opiate users.
Wolff K; Rostami-Hodjegan A; Shires S; Hay AW; Feely M; Calvert R; Raistrick D; Tucker GT
Br J Clin Pharmacol; 1997 Oct; 44(4):325-34. PubMed ID: 9354306
[TBL] [Abstract][Full Text] [Related]
4. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.
Mitchell TB; Dyer KR; Newcombe D; Salter A; Somogyi AA; Bochner F; White JM
Br J Clin Pharmacol; 2004 Dec; 58(6):609-17. PubMed ID: 15563359
[TBL] [Abstract][Full Text] [Related]
5. Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.
Hanna J; Foster DJ; Salter A; Somogyi AA; White JM; Bochner F
Br J Clin Pharmacol; 2005 Oct; 60(4):404-13. PubMed ID: 16187972
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of methadone enantiomers in hospice patients with cancer pain.
Auret K; Roger Goucke C; Ilett KF; Page-Sharp M; Boyd F; Oh TE
Ther Drug Monit; 2006 Jun; 28(3):359-66. PubMed ID: 16778720
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapy.
Liu P; Foster G; Labadie R; Somoza E; Sharma A
Antimicrob Agents Chemother; 2007 Jan; 51(1):110-8. PubMed ID: 17074798
[TBL] [Abstract][Full Text] [Related]
8. Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.
Eap CB; Buclin T; Baumann P
Clin Pharmacokinet; 2002; 41(14):1153-93. PubMed ID: 12405865
[TBL] [Abstract][Full Text] [Related]
9. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.
Dyer KR; Foster DJ; White JM; Somogyi AA; Menelaou A; Bochner F
Clin Pharmacol Ther; 1999 Jun; 65(6):685-94. PubMed ID: 10391674
[TBL] [Abstract][Full Text] [Related]
10. Population Genetic-Based Pharmacokinetic Modeling of Methadone and its Relationship with the QTc Interval in Opioid-Dependent Patients.
Csajka C; Crettol S; Guidi M; Eap CB
Clin Pharmacokinet; 2016 Dec; 55(12):1521-1533. PubMed ID: 27286724
[TBL] [Abstract][Full Text] [Related]
11. Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment.
Shiran MR; Lennard MS; Iqbal MZ; Lagundoye O; Seivewright N; Tucker GT; Rostami-Hodjegan A
Br J Clin Pharmacol; 2009 Jan; 67(1):29-37. PubMed ID: 19133059
[TBL] [Abstract][Full Text] [Related]
12. Steady-state pharmacokinetics of methadone in opioid addicts.
Wolff K; Hay AW; Raistrick D; Calvert R
Eur J Clin Pharmacol; 1993; 44(2):189-94. PubMed ID: 8453965
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with amprenavir in opioid-dependent subjects.
Hendrix CW; Wakeford J; Wire MB; Lou Y; Bigelow GE; Martinez E; Christopher J; Fuchs EJ; Snidow JW
Pharmacotherapy; 2004 Sep; 24(9):1110-21. PubMed ID: 15460171
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and pharmacodynamics of methadone enantiomers after coadministration with fosamprenavir-ritonavir in opioid-dependent subjects.
Cao YJ; Smith PF; Wire MB; Lou Y; Lancaster CT; Causon RC; Bigelow GE; Martinez E; Fuchs EJ; Radebaugh C; McCabe S; Hendrix CW
Pharmacotherapy; 2008 Jul; 28(7):863-74. PubMed ID: 18576901
[TBL] [Abstract][Full Text] [Related]
15. Lack of influence of CYP2D6 genotype on the clearance of (R)-, (S)- and racemic-methadone.
Coller JK; Joergensen C; Foster DJ; James H; Gillis D; Christrup L; Somogyi AA
Int J Clin Pharmacol Ther; 2007 Jul; 45(7):410-7. PubMed ID: 17725248
[TBL] [Abstract][Full Text] [Related]
16. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of methadone enantiomers after a single oral dose of racemate.
Boulton DW; Arnaud P; DeVane CL
Clin Pharmacol Ther; 2001 Jul; 70(1):48-57. PubMed ID: 11452244
[TBL] [Abstract][Full Text] [Related]
18. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study.
Bart G; Lenz S; Straka RJ; Brundage RC
Drug Alcohol Depend; 2014 Dec; 145():185-93. PubMed ID: 25456329
[TBL] [Abstract][Full Text] [Related]
19. Population-based pharmacokinetic approach for methadone monitoring of opiate addicts: potential clinical utility.
Wolff K; Rostami-Hodjegan A; Hay AW; Raistrick D; Tucker G
Addiction; 2000 Dec; 95(12):1771-83. PubMed ID: 11177493
[TBL] [Abstract][Full Text] [Related]
20. Effect of tenofovir disoproxil fumarate on the pharmacokinetics and pharmacodynamics of total, R-, and S-methadone.
Smith PF; Kearney BP; Liaw S; Cloen D; Bullock JM; Haas CE; Yale K; Booker BM; Berenson CS; Coakley DF; Flaherty JF
Pharmacotherapy; 2004 Aug; 24(8):970-7. PubMed ID: 15338845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
